Table 1.
Characteristics of patients
| Flutamide group (n = 11) | Bicalutamide group (n = 11) | P | |
|---|---|---|---|
| Age (median, years) | 79 (71–86) | 79 (67–82) | 0.84† |
| PSA (median, ng/mL) | 12.4 (4.7–17.6) | 10.4 (3.8–38.6) | 0.69† |
| Testosterone (median, ng/mL) | 4.7 (2.0–9.4) | 4.5 (2.8–7.7) | 0.90† |
| DHEA (median, ng/mL) | 59 (18–167) | 73 (36–230) | 0.09† |
| Angiostenegione (median, ng/mL) | 1.2 (0.6–1.9) | 1.5 (0.9–3.0) | 0.11† |
| Gleason score | |||
| 6 | 2 | 3 | 0.91‡ |
| 7 | 9 | 8 | |
| 8–10 | 0 | 0 | |
| Clinical T stage | |||
| T1 | 5 | 6 | 0.62‡ |
| T2 | 5 | 5 | |
| T3 | 1 | 0 | |
| T4 | 0 | 0 | |
† Mann–Whitney U test; ‡ chi-square test